{"id":47746,"date":"2022-08-29T14:02:03","date_gmt":"2022-08-29T12:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/"},"modified":"2022-08-29T14:02:03","modified_gmt":"2022-08-29T12:02:03","slug":"tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/","title":{"rendered":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022"},"content":{"rendered":"
\n

\n-TQS-168 demonstrated robust geroprotective effects in preclinical studies-<\/i>\n<\/p>\n

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a,<\/i> at ARDD 2022, the 9th<\/sup> Aging Research and Drug Discovery meeting, taking place August 29 to September 2, 2022 at the University of Copenhagen, Denmark.\n<\/p>\n

<\/a><\/p>\n

\nIn the preclinical study conducted in 18-month-old mice, it was shown that treatment for four months with TQS-168 resulted in a 66% improvement in the 31-point Frailty Index, a commonly used measurement to evaluate aging-related changes in mice. Treatment with TQS-168 also resulted in improvements in grip strength and treadmill running endurance, and a reduction in fat mass with no change in lean mass. These results indicate that TQS-168 has robust geroprotective effects in mice.\n<\/p>\n

\nTQS-168 was found to be well tolerated in healthy adult male subjects in a Phase 1 clinical trial. Adverse events were mild and transient, and no abnormalities were observed in laboratory parameters, ECG, or vital signs. No serious adverse events occurred. TQS-168 is ready for clinical trials to evaluate its potential to impact human aging and quality of life in the elderly. Tranquis is also advancing TQS-168 into clinical studies in other indications.\n<\/p>\n

\nAbout TQS-168 and PGC-1a<\/i><\/b>\n<\/p>\n

\nTQS-168 is a PGC-1a<\/i>-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a<\/i> modulation plays a critical role. PGC-1a<\/i> is a transcriptional coactivator that regulates genes involved in cell energy metabolism, acting as a key regulator of mitochondrial biogenesis, giving TQS-168 potential as a target in a broad spectrum of diseases. TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson\u2019s disease. TQS-168 also demonstrated compelling biomarker data, including increased PGC-1a<\/i> gene expression, reduction of inflammatory monocytes and cytokines, and reduced levels of neurofilament light in animal models. In vitro, TQS-168 also shows specific immunomodulatory effects in myeloid cell lines and in white blood cells from people living with ALS.\n<\/p>\n

\nAbout Tranquis<\/b>\n<\/p>\n

\nTranquis is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of modulating PGC-1a<\/i> to restore normal cell homeostasis and function. Tranquis\u2019 platform has the potential to revolutionize the management of an entire range of indications in the fields of neurodegeneration, mitochondrial diseases, immuno-inflammation, and immunosenescence. In addition, the Company\u2019s approach may promote healthy aging and longevity.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors
\n
investors@tranquis.com<\/a><\/p>\n

Media
\n
Cory Tromblee
\n
media@tranquis.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47746","6":"format-standard","7":"category-industry"},"yoast_head":"\nTranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-29T12:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022\",\"datePublished\":\"2022-08-29T12:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/\"},\"wordCount\":447,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005230\\\/en\\\/1555067\\\/21\\\/Tranquis_Logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/\",\"name\":\"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005230\\\/en\\\/1555067\\\/21\\\/Tranquis_Logo_RGB.jpg\",\"datePublished\":\"2022-08-29T12:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005230\\\/en\\\/1555067\\\/21\\\/Tranquis_Logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005230\\\/en\\\/1555067\\\/21\\\/Tranquis_Logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/","og_locale":"en_US","og_type":"article","og_title":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend","og_description":"-TQS-168 demonstrated robust geroprotective effects in preclinical studies- REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1a, at ARDD ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-29T12:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022","datePublished":"2022-08-29T12:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/"},"wordCount":447,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/","url":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/","name":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg","datePublished":"2022-08-29T12:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220829005230\/en\/1555067\/21\/Tranquis_Logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tranquis-therapeutics-to-present-preclinical-data-on-tqs-168-at-ardd-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47746"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47746\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}